INSTYTUT MATKI I DZIECKA
A United Kingdom buyer, with 11 published contracts, worth £12.1m, most recently 7 months ago.
Top 5 suppliers won 95% of awarded value — £22.9m of £24.2m across 6 awards.
The contract involves the procurement of newborn screening kits for the detection of lysosomal storage diseases, specifically: Pompe disease (measuring alpha-glucosidase activity), Fabry disease (measuring alpha-galactosidase A activity), Gaucher disease (measuring glucocerebrosidase activity), and
This contract involves providing insurance services for property, electronic equipment, vehicle insurance, mandatory liability insurance for healthcare providers, voluntary liability insurance for healthcare providers, voluntary liability insurance related to business activities and owned property,
This contract involves the supply of the medication Burosumab as part of a treatment program for patients with X-Linked Hypophosphatemia (XLH), classified under ICD-10 code E.83.3. The contracting authority does not allow partial bids, meaning the contract cannot be divided into smaller parts. Addit
